The U.S. FDA has granted Opticyte Inc. a breakthrough device designation for its Cell O₂ patient monitor, a noninvasive technology for monitoring patients at risk of organ failure. The device could help to reduce serious illness and deaths by alerting clinicians to patients experiencing organ failure before irreversible damage occurs.